Dr Lalchandani Labs Ltd (DLCL) — shareholding pattern, promoter holding, financials and share price
About Dr Lalchandani Labs Ltd (DLCL)
Dr Lalchandani Labs Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as DLCL and on the BSE under scrip code 541299. Its ISIN is INE871Z01013.
Incorporated in 2011, Dr. Lalchandani Labs Ltd is in the business of running laboratories for pathological investigations [1]
Dr Lalchandani Labs Limited is a diagnostic and healthcare service provider in Delhi/NCR, offering a range of pathology and diagnostic tests.
The company was established in 2011 and transitioned from a partnership firm to a limited company in 2017.
Listed peers in Healthcare Service Provider: Dhanvantri Jeevan Rekha Ltd, Clinitech Laboratory Ltd, Looks Health Services Ltd, Ashram Online.com Ltd, Gian Lifecare Ltd, Boston Commerce Limited.
Valuation & Returns
10 Jul 2026At ₹8.35 a share on 10 Jul 2026, Dr Lalchandani Labs Ltd (DLCL) was valued at a price-to-earnings ratio of 117.57x against an industry P/E of 61.73x and a price-to-book of 0.5x on a book value of ₹16.35 per share. Solomo computes return on equity of 0.45% and return on capital employed of 0.71% from filed results.
- P/E
- 117.57x
- Industry P/E
- 61.73x
- P/B
- 0.5x
- EPS (TTM)
- ₹0.07
- Book value / share
- ₹16.35
- ROE
- 0.45%
- ROCE
- 0.71%
- ROA
- 0.4%
- Debt / equity
- 0.15x
- Dividend yield
- 0%
- EBITDA margin
- 16.27%
- 52-week range
- ₹6.46 – ₹21.22
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Dr Lalchandani Labs Ltd (DLCL) reported revenue of ₹4.19 crore, net profit of ₹0.06 crore and earnings per share of ₹0.07. That compares with revenue of ₹4.45 crore and net profit of ₹0.42 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2.13 crore and net profit ₹-0.13 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 11.28 | 5.04 | 4.81 | 4.45 | 4.19 |
| Net profit (₹ cr) | 0.93 | -1.56 | 0.62 | 0.42 | 0.06 |
| EPS (₹) | 1.07 | -1.79 | 0.71 | 0.48 | 0.07 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | -6.11% | -26.63% | -7.48% |
| Profit growth | -2.53% | -23.54% | -32.26% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 32.9% of Dr Lalchandani Labs Ltd (DLCL). Market capitalisation was ₹7 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2018.
Largest disclosed public shareholders in Mar 2026: ANURAAG GAMBHIR 15.05%, HARSHPAUL SINGH TAKKAR 5.79%, AMIT CHARAN 2.55%, LAXMIPAT DUDHERIA 2.55%, LUXMI KANT GUPTA 2.13%, SUHITH PUNDALIKA BANGERA 1.9%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 32.9% | - | - | - | 67.1% |
| Sep 2025 | 31.15% | - | - | - | 68.85% |
| Mar 2025 | 48.32% | - | - | - | 51.68% |
| Sep 2024 | 57.18% | - | - | - | 42.82% |
| Mar 2024 | 60.78% | - | - | - | 39.22% |
| Sep 2023 | 60.78% | - | - | - | 39.22% |
| Mar 2023 | 60.78% | - | - | - | 39.22% |
| Sep 2022 | 60.78% | - | - | - | 39.22% |